Ministry of Health grants registration for circulation of Russian targeted cancer drugs

(Chinhphu.vn) - That is the drug Pembroria, whose main active ingredient is Pembrolizumab. This drug has been available in Vietnam for several years now, used for targeted therapy in many groups of cancers. The Russian drug this time is a similar biological product.

Pembroria medicine has the main active ingredient Pembrolizumab.

Specifically, according to Decision No. 628/QD-QLD dated October 31 issued by the Department of Drug Administration, Ministry of Health , there are 14 vaccines and biological products that have been granted a circulation registration certificate in Vietnam with a validity of 3 years - batch 57.

Among them, there is the drug Pembroria (main active ingredient is Pembrolizumab, content 100mg/4ml) produced by Limited Liability Company "PK-137" (Russia), a facility registered in the United Arab Emirates.

Pembroria medicine is prepared in the form of a concentrated solution for infusion, with a shelf life of 24 months from the date of manufacture.

Speaking to reporters, Mr. Ta Manh Hung, Deputy Director of the Department of Drug Administration, Ministry of Health, said that information from the Department of Drug and Biological Product Registration shows that the reference biological product has been granted a circulation registration certificate for many years. This drug Pembroria is produced by Russia, is a similar biological product, and has just been granted a circulation registration certificate.

Currently, in our country there are many drugs with effects and indications such as Pembroria that have been granted circulation registration.

Patients have more opportunities to access targeted therapy drugs.

As a cancer treatment expert for decades, speaking to reporters, Associate Professor, Dr. Pham Cam Phuong, Director of the Center for Nuclear Medicine and Oncology, Bach Mai Hospital, also said that this is a targeted treatment drug for cancer, which has been available in Vietnam for many years. This drug, produced by Russia, is a similar biological product, newly licensed in Vietnam. This will help patients have more opportunities to be treated at a more suitable price.

According to the instructions for use of the Russian drug Pembroria, this drug is indicated for the treatment of melanoma, non-small cell lung carcinoma, squamous cell carcinoma of the head and neck, classical Hodgkin lymphoma, urothelial carcinoma, esophageal carcinoma, colorectal cancer, cervical cancer, renal cell carcinoma, endometrial carcinoma, triple-negative breast cancer, adenocarcinoma of the stomach or gastroesophageal junction, and biliary tract carcinoma.

The granting of additional registration number for the Russian drug Pembroria in Vietnam is of great significance in the context of the current great demand for advanced cancer treatment drugs in our country and increasing access to modern treatment methods for patients.

Hien Minh

Source: https://baochinhphu.vn/bo-y-te-cap-dang-ky-luu-hanh-thuoc-dieu-tri-dich-trong-ung-thu-cua-nga-102251111200337298.htm